No significant reduction reported in mortality, ventilatory support, ICU admission, length of stay, serious adverse events; increase seen in adverse events, diarrhea.
In a meta-analysis of six studies evaluating colchicine as a COVID-19 treatment, the anti-inflammatory drug for acute gout attacks did not appear to improve outcomes for patients.